“…Although MAO-B inhibitors are used to treat PD, they act irreversibly, which has drawbacks and is spurring new investigations toward the design of reversible MAO-B inhibitors . Chalcones and flavones were reported as potent and selective inhibitors of MAO-B. − Recently, Iacovino et al synthesized a series of noncytotoxic chalcones with nanomolar K i values and high selectivity toward MAO-B isoenzymes . Dietary flavones, including acacetin, baicalein, luteolin, apigenin, and nobiletin, showed beneficial effects in protecting dopamine neurons in PD models in vitro and in vivo . , Low bioavailability of flavonoids results from poor absorption, rapid excretion, and the extensive conjugation and biotransformation that occur during their absorption. , Novel strategies to enhance the bioavailability of dietary flavonoids have been developed, which comprises unusual delivery systems, including solid dispersion, emulsions, crystal engineering preparation, phytosome and cyclodextrin complexes, nanocrystal, nanoparticles, polymeric micelles, and liposomes, among others .…”